JPH11504330A - カリウムチャンネル遮断剤の投与により、哺乳動物の眼圧を降下する方法 - Google Patents
カリウムチャンネル遮断剤の投与により、哺乳動物の眼圧を降下する方法Info
- Publication number
- JPH11504330A JPH11504330A JP8532585A JP53258596A JPH11504330A JP H11504330 A JPH11504330 A JP H11504330A JP 8532585 A JP8532585 A JP 8532585A JP 53258596 A JP53258596 A JP 53258596A JP H11504330 A JPH11504330 A JP H11504330A
- Authority
- JP
- Japan
- Prior art keywords
- potassium channel
- blocking activity
- pharmaceutical composition
- channel blocking
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/49—Cinchonan derivatives, e.g. quinine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1767—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.哺乳動物の眼圧を降下するのに有用な薬剤組成物であって、カリウムチャ ンネル遮断活性を有する化合物1種またはそれ以上を活性成分として含有する薬 剤組成物。 2.カリウムチャンネル遮断活性を有する化合物は、キニーネ、振戦誘発性イ ンドールアルカロイド、および昆虫毒素から成る群から選択する請求項1記載の 薬剤組成物。 3.前記化合物は、キニーネ、ペニトレムA、パスパリシン、カリブドトキシ ンおよびイベリオトキシンから成る群から選択する請求項2記載の薬剤組成物。 4.カリウムチャンネル遮断活性を有する化合物はキニーネである請求項2記 載の薬剤組成物。 5.カリウムチャンネル遮断活性を有する化合物はカリブドトキシンである請 求項2記載の薬剤組成物。 6.哺乳動物の眼に点眼剤として投与するのに適した眼用溶液である請求項2 記載の薬剤組成物。 7.カリウムチャンネル遮断活性を有する化合物を、約0.0001〜1%(w /v)含有する請求項2記載の薬剤組成物。 8.哺乳動物の眼において神経保護作用を提供するのに有用な薬剤組成物であ って、カリウムチャンネル遮断活性を有する化合物1種またはそれ以上を活性成 分として含有する薬剤組成物。 9.カリウムチャンネル遮断活性を有する化合物は、振戦誘発性インドールア ルカロイド、および昆虫毒素から成る群から選択する請求項8記載の薬剤組成物 。 10.前記化合物は、キニーネ、ペニトレムA、パスパリシン、カリブドトキ シンおよびイベリオトキシンから成る群から選択する請求項9記載の薬剤組成物 。 11.カリウムチャンネル遮断活性を有する化合物はキニーネである請求項9 記載の薬剤組成物。 12.カリウムチャンネル遮断活性を有する化合物はカリブドトキシンである 請求項9記載の薬剤組成物。 13.カリウムチャンネル遮断活性を有する化合物を、約0.0001〜1%( w/v)含有する請求項9記載の薬剤組成物。 14.ヒトを包含する哺乳動物の眼圧を降下する目的で哺乳動物を処置する方 法であって、カリウムチャンネル遮断活性を有する化合物1種またはそれ以上を 活性成分として含有する薬剤組成物を哺乳動物に投与することを含んで成る処置 方法。 15.カリウムチャンネル遮断活性を有する化合物は、キニーネ、振戦誘発性 インドールアルカロイド、および昆虫毒素から成る群から選択する請求項14記 載の方法。 16.前記化合物は、キニーネ、ペニトレムA、パスパリシン、カリブドトキ シンおよびイベリオトキシンから成る群から選択する請求項15記載の方法。 17.カリウムチャンネル遮断活性を有する化合物はキニーネである請求項1 5記載の方法。 18.カリウムチャンネル遮断活性を有する化合物はカリブドトキシンである 請求項15記載の方法。 19.組成物が、哺乳動物の眼に点眼剤として投与するのに適した眼用溶液で ある請求項15記載の処置方法。 20.眼用組成物において、カリウムチャンネル遮断活性を有する化合物の濃 度範囲が約0.0001〜1%(w/v)である請求項15記載の処置方法。 21.哺乳動物の眼に神経保護作用を提供する方法であって、カリウムチャン ネル遮断活性を有する化合物1種またはそれ以上を活性成分として含有する薬剤 組成物を哺乳動物に投与することを含んで成る方法。 22.カリウムチャンネル遮断活性を有する化合物は、キニーネ、振戦誘発性 インドールアルカロイド、および昆虫毒素から成る群から選択する請求項20記 載の方法。 23.前記化合物は、キニーネ、ペニトレムA、パスパリシン、カリブドトキ シンおよびイベリオトキシンから成る群から選択する請求項22記載の方法。 24.カリウムチャンネル遮断活性を有する化合物はキニーネである請求項2 2記載の方法。 25.カリウムチャンネル遮断活性を有する化合物はカリブドトキシンである 請求項22記載の方法。 26.組成物は、カリウムチャンネル遮断活性を有する化合物を、約0.00 01〜1%(w/v)含有する請求項22記載の方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/431,170 | 1995-04-28 | ||
US08/431,170 US5573758A (en) | 1995-04-28 | 1995-04-28 | Method for reducing intraocular pressure in the mammalian eye by administration of potassium channel blockers |
PCT/US1996/005241 WO1996033719A1 (en) | 1995-04-28 | 1996-04-16 | Method for reducing intraocular pressure in the mammalian eye by administration of potassium channel blockers |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2007150243A Division JP2007217437A (ja) | 1995-04-28 | 2007-06-06 | カリウムチャンネル遮断剤の投与により、哺乳動物の眼圧を降下する方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
JPH11504330A true JPH11504330A (ja) | 1999-04-20 |
Family
ID=23710776
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP8532585A Withdrawn JPH11504330A (ja) | 1995-04-28 | 1996-04-16 | カリウムチャンネル遮断剤の投与により、哺乳動物の眼圧を降下する方法 |
JP2007150243A Pending JP2007217437A (ja) | 1995-04-28 | 2007-06-06 | カリウムチャンネル遮断剤の投与により、哺乳動物の眼圧を降下する方法 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2007150243A Pending JP2007217437A (ja) | 1995-04-28 | 2007-06-06 | カリウムチャンネル遮断剤の投与により、哺乳動物の眼圧を降下する方法 |
Country Status (8)
Country | Link |
---|---|
US (1) | US5573758A (ja) |
EP (2) | EP0825863B1 (ja) |
JP (2) | JPH11504330A (ja) |
AT (2) | ATE225658T1 (ja) |
AU (1) | AU703241B2 (ja) |
DE (2) | DE69624234D1 (ja) |
ES (2) | ES2182973T3 (ja) |
WO (1) | WO1996033719A1 (ja) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010137547A1 (ja) * | 2009-05-25 | 2010-12-02 | 国立大学法人東京工業大学 | 中枢神経細胞の増殖及び分化に係る中核因子を含む医薬組成物 |
US9365640B2 (en) | 2011-04-29 | 2016-06-14 | Celgene Corporation | Methods for the treatment of cancer and inflammatory diseases using cereblon as a predictor |
US9587281B2 (en) | 2012-08-14 | 2017-03-07 | Celgene Corporation | Cereblon isoforms and their use as biomarkers for therapeutic treatment |
US9857359B2 (en) | 2012-06-29 | 2018-01-02 | Celgene Corporation | Methods for determining drug efficacy using cereblon-associated proteins |
US10092555B2 (en) | 2014-06-27 | 2018-10-09 | Celgene Corporation | Compositions and methods for inducing conformational changes in cereblon and other E3 ubiquitin ligases |
US10830762B2 (en) | 2015-12-28 | 2020-11-10 | Celgene Corporation | Compositions and methods for inducing conformational changes in cereblon and other E3 ubiquitin ligases |
Families Citing this family (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP3719609B2 (ja) | 1995-12-21 | 2005-11-24 | アルコン ラボラトリーズ,インコーポレイテッド | 緑内障および眼虚血の治療のための特定のイソキノリンスルホニル化合物の使用 |
US5925342A (en) * | 1996-11-13 | 1999-07-20 | Allergan | Method for reducing intraocular pressure in the mammalian eye by administration of potassium channel blockers |
ATE409491T1 (de) * | 2000-01-18 | 2008-10-15 | Merck & Co Inc | Orhthalmologische zusammenstellungen zur behandlung von ocularer hypertension |
US6548535B2 (en) * | 2000-01-18 | 2003-04-15 | Merck & Co., Inc. | Method for treating ocular hypertension |
JP2005503761A (ja) * | 2001-01-30 | 2005-02-10 | メルク エンド カムパニー インコーポレーテッド | Maxi−kチャネル遮断薬を特定する方法 |
JP2004520379A (ja) * | 2001-01-30 | 2004-07-08 | メルク エンド カムパニー インコーポレーテッド | 高眼圧治療用眼薬組成物 |
US20040115739A1 (en) * | 2002-01-25 | 2004-06-17 | Garcia Maria L | Method for identifying maxi-k channel blockers for use in lowering elevated intraocular pressure using hek-293 cells |
US7119112B2 (en) * | 2002-02-28 | 2006-10-10 | Icagen, Inc. | Sulfonamides as potassium channel blockers |
EP1487430A4 (en) * | 2002-02-28 | 2007-08-22 | Icagen Inc | METHOD FOR THE TREATMENT OF DISEASES RELATED TO THE EYE REMINDER |
WO2003077845A2 (en) * | 2002-03-15 | 2003-09-25 | Merck & Co., Inc. | Compositions and methods for treating glaucoma and ocular hypertension |
AU2003239972B2 (en) * | 2002-06-14 | 2008-02-28 | Merck & Co., Inc. | Ophthalmic compositions for treating ocular hypertension |
JP2005533055A (ja) * | 2002-06-17 | 2005-11-04 | メルク エンド カムパニー インコーポレーテッド | 新規マキシkチャンネルブロッカー、その使用方法および製造方法 |
US20050239787A1 (en) * | 2002-06-17 | 2005-10-27 | Goetz Michael A | Novel maxi-k channel blockers, methods of use and process for making the same |
US7528163B2 (en) * | 2002-11-08 | 2009-05-05 | Merck & Co. Inc. | Ophthalmic compositions for treating ocular hypertension |
US7196082B2 (en) | 2002-11-08 | 2007-03-27 | Merck & Co. Inc. | Ophthalmic compositions for treating ocular hypertension |
CA2519899A1 (en) | 2003-03-27 | 2004-10-14 | Merck & Co., Inc. | Ophthalmic compositions for treating ocular hypertension |
US20060148805A1 (en) * | 2003-07-01 | 2006-07-06 | Meng Hsin Chen | Opthalmic compositions for treating ocular hypertension |
US7576122B2 (en) * | 2003-09-02 | 2009-08-18 | Merck & Co. Inc. | Ophthalmic compositions for treating ocular hypertension |
CN1845904A (zh) * | 2003-09-04 | 2006-10-11 | 默克公司 | 用于治疗高眼压的眼用组合物 |
JP2007504236A (ja) * | 2003-09-04 | 2007-03-01 | メルク エンド カムパニー インコーポレーテッド | 高眼圧症を治療するための眼用組成物 |
US20050250779A1 (en) * | 2004-05-04 | 2005-11-10 | Song Zhu | Pteridinone derivatives for treating ocular hypertension |
AU2005274972A1 (en) | 2004-07-20 | 2006-02-23 | Merck & Co., Inc. | Ophthalmic compositions for treating ocular hypertension |
US20080097108A1 (en) * | 2004-10-13 | 2008-04-24 | Ying-Duo Gao | Ophthalmic Compositions for Treating Ocular Hypertension |
CN101035526A (zh) * | 2004-10-13 | 2007-09-12 | 默克公司 | 用于治疗高眼压的眼用组合物 |
EP2004193A2 (en) * | 2006-03-13 | 2008-12-24 | Merck & Co., Inc. | Ophthalmic compositions for treating ocular hypertension |
JP2009541219A (ja) * | 2006-06-12 | 2009-11-26 | メルク エンド カムパニー インコーポレーテッド | 高眼圧治療のための眼科組成物 |
EP1941876A1 (en) * | 2006-12-28 | 2008-07-09 | Lacer, S.A. | Isosorbide mononitrate derivatives for the treatment of Inflammation and ocular hypertension |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1989010757A1 (en) * | 1988-05-10 | 1989-11-16 | Leo Pharmaceutical Products Ltd. A/S (Løvens Kemis | New ophthalmic preparation for treating glaucoma |
EP0430621A3 (en) * | 1989-11-29 | 1992-03-04 | Beecham Group P.L.C. | Process for the preparation of chiral 3,4-epoxy benzopyrans |
US5512591A (en) * | 1993-02-18 | 1996-04-30 | President And Fellows Of Harvard College | Treatments for diseases characterized by neovascularization |
CA2164733A1 (en) * | 1993-06-08 | 1994-12-22 | Nino Sorgente | Methods and compositions for lowering intraocular pressure |
US5494895A (en) * | 1993-07-22 | 1996-02-27 | Merck & Co., Inc. | Scorpion peptide margatoxin with immunosuppressant activity |
GB9316111D0 (en) * | 1993-08-04 | 1993-09-22 | Pfizer Ltd | Benzopyrans |
-
1995
- 1995-04-28 US US08/431,170 patent/US5573758A/en not_active Expired - Lifetime
-
1996
- 1996-04-16 AU AU55488/96A patent/AU703241B2/en not_active Ceased
- 1996-04-16 DE DE69624234T patent/DE69624234D1/de not_active Expired - Lifetime
- 1996-04-16 ES ES96912798T patent/ES2182973T3/es not_active Expired - Lifetime
- 1996-04-16 JP JP8532585A patent/JPH11504330A/ja not_active Withdrawn
- 1996-04-16 ES ES02009867T patent/ES2204879T5/es not_active Expired - Lifetime
- 1996-04-16 EP EP96912798A patent/EP0825863B1/en not_active Expired - Lifetime
- 1996-04-16 WO PCT/US1996/005241 patent/WO1996033719A1/en active IP Right Grant
- 1996-04-16 DE DE69630325T patent/DE69630325T3/de not_active Expired - Lifetime
- 1996-04-16 AT AT96912798T patent/ATE225658T1/de not_active IP Right Cessation
- 1996-04-16 AT AT02009867T patent/ATE251458T1/de not_active IP Right Cessation
- 1996-04-16 EP EP02009867A patent/EP1243270B2/en not_active Expired - Lifetime
-
2007
- 2007-06-06 JP JP2007150243A patent/JP2007217437A/ja active Pending
Cited By (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9611465B2 (en) | 2009-05-25 | 2017-04-04 | Celgene Corporation | Pharmaceutical composition containing core factor involved in proliferation and differentiation of central nervous cell |
EP2436387A1 (en) * | 2009-05-25 | 2012-04-04 | Tokyo Institute of Technology | Pharmaceutical composition containing nuclear factor involved in proliferation and differentiation of central neuronal cells |
EP2436387A4 (en) * | 2009-05-25 | 2013-07-17 | Tokyo Inst Tech | PHARMACEUTICAL COMPOSITION COMPRISING A NUCLEAR FACTOR INVOLVED IN THE PROLIFERATION AND DIFFERENTIATION OF CELLS OF THE CENTRAL NERVOUS SYSTEM |
JP5645816B2 (ja) * | 2009-05-25 | 2014-12-24 | 国立大学法人東京工業大学 | 中枢神経細胞の増殖及び分化に係る中核因子を含む医薬組成物 |
WO2010137547A1 (ja) * | 2009-05-25 | 2010-12-02 | 国立大学法人東京工業大学 | 中枢神経細胞の増殖及び分化に係る中核因子を含む医薬組成物 |
US9365640B2 (en) | 2011-04-29 | 2016-06-14 | Celgene Corporation | Methods for the treatment of cancer and inflammatory diseases using cereblon as a predictor |
US10047151B2 (en) | 2011-04-29 | 2018-08-14 | Celgene Corporation | Methods for the treatment of cancer and inflammatory diseases using cereblon as a predictor |
US9857359B2 (en) | 2012-06-29 | 2018-01-02 | Celgene Corporation | Methods for determining drug efficacy using cereblon-associated proteins |
US9587281B2 (en) | 2012-08-14 | 2017-03-07 | Celgene Corporation | Cereblon isoforms and their use as biomarkers for therapeutic treatment |
US10668057B2 (en) | 2014-06-27 | 2020-06-02 | Celgene Corporation | Compositions and methods for inducing conformational changes in cereblon and other E3 ubiquitin ligases |
US10092555B2 (en) | 2014-06-27 | 2018-10-09 | Celgene Corporation | Compositions and methods for inducing conformational changes in cereblon and other E3 ubiquitin ligases |
US11419861B2 (en) | 2014-06-27 | 2022-08-23 | Celgene Corporation | Compositions and methods for inducing conformational changes in cereblon and other E3 ubiquitin ligases |
US10830762B2 (en) | 2015-12-28 | 2020-11-10 | Celgene Corporation | Compositions and methods for inducing conformational changes in cereblon and other E3 ubiquitin ligases |
US11733233B2 (en) | 2015-12-28 | 2023-08-22 | Celgene Corporation | Compositions and methods for inducing conformational changes in cereblon and other E3 ubiquitin ligases |
Also Published As
Publication number | Publication date |
---|---|
US5573758A (en) | 1996-11-12 |
DE69630325T3 (de) | 2009-11-19 |
ES2182973T3 (es) | 2003-03-16 |
DE69630325D1 (de) | 2003-11-13 |
DE69624234D1 (de) | 2002-11-14 |
EP0825863B1 (en) | 2002-10-09 |
ATE225658T1 (de) | 2002-10-15 |
AU5548896A (en) | 1996-11-18 |
EP1243270B2 (en) | 2009-03-25 |
AU703241B2 (en) | 1999-03-25 |
WO1996033719A1 (en) | 1996-10-31 |
ATE251458T1 (de) | 2003-10-15 |
ES2204879T3 (es) | 2004-05-01 |
ES2204879T5 (es) | 2009-06-19 |
EP1243270A1 (en) | 2002-09-25 |
JP2007217437A (ja) | 2007-08-30 |
DE69630325T2 (de) | 2004-07-29 |
EP1243270B1 (en) | 2003-10-08 |
EP0825863A1 (en) | 1998-03-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JPH11504330A (ja) | カリウムチャンネル遮断剤の投与により、哺乳動物の眼圧を降下する方法 | |
US5925342A (en) | Method for reducing intraocular pressure in the mammalian eye by administration of potassium channel blockers | |
US4476140A (en) | Composition and method for treatment of glaucoma | |
CA2496797C (en) | Therapeutic agent for glaucoma comprising rho kinase inhibitor and prostaglandin | |
EP0735868B1 (en) | Use of non-steroidal cyclooxygenase inhibitors for the manufacture of a medicament for the treatment of elevated intraocular pressure | |
JP4934653B2 (ja) | Rhoキナーゼ阻害剤とβ遮断薬からなる緑内障治療剤 | |
Williams et al. | Effects of timolol, betaxolol, and levobunolol on human tenon's fibroblasts in tissue culture. | |
AU709322B2 (en) | Use of chloride channel blockers for reducing intraocular pressure | |
US20040216749A1 (en) | Vasomodulation during glaucoma surgery | |
JP2004518612A (ja) | インドール誘導体を用いて眼圧を下降させる方法 | |
JP2001508035A (ja) | 炭酸脱水酵素阻害薬及びキサンタンガムを含有する眼科用組成物 | |
JP2001521500A (ja) | 緑内障に関連する視神経変性を防止する薬剤の製造におけるナトリウムチャンネル遮断剤の使用 | |
BG64525B1 (bg) | Използване инхибиторите на карбоанхидразата за лечение на оток на макулата | |
US5578638A (en) | Treatment of glaucoma and ocular hypertension with β3 -adrenergic agonists | |
JPS6225645B2 (ja) | ||
JPH08511024A (ja) | 眼内圧を低下させる方法および組成物 | |
RU2434633C2 (ru) | Фармацевтические препаративные формы латрункулина | |
CA2219280C (en) | Method for reducing intraocular pressure in the mammalian eye by administration of potassium channel blockers | |
US5563171A (en) | Treatment of glaucoma and ocular hypertension with β3-adrenergic agonists | |
AU723823B2 (en) | Use of chloride channel blockers for providing a neuroprotective effect to the mammalian eye | |
EP0456988B1 (en) | Use of naproxen as mydriatic agent | |
JP2002356431A (ja) | ステロイドを有効成分とする網脈絡膜疾患治療剤 | |
Borhani et al. | Vitreoretinal toxicity of acetazolamide following intravitreal administration in the rabbit eye | |
KR20080068881A (ko) | 안압 강하제인 숙신이미드 유도체 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20060509 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20060808 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20060925 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20061109 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20070206 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20070507 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20070606 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20070809 |
|
A912 | Re-examination (zenchi) completed and case transferred to appeal board |
Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20071115 |
|
A761 | Written withdrawal of application |
Free format text: JAPANESE INTERMEDIATE CODE: A761 Effective date: 20090616 |